ArticleCancers2021

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7).

Hisato Kawakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.